當前位置：首頁 JCRQ1 期刊介紹(非官網(wǎng))

Journal Of Drug TargetingSCIE

國際簡稱：J DRUG TARGET 參考譯名：藥物靶向雜志

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：1061-186X; E-ISSN：1029-2330; 是否OA：未開放; 是否預警：否; TOP期刊：否

出版信息：: 出版地區(qū)：ENGLAND; 出版商：Informa Healthcare; 出版語言：English; 出版周期：Bimonthly; 出版年份：1993; 研究方向：醫(yī)學-藥學

評價信息：: 影響因子：4.3; H-index：80; CiteScore指數(shù)：9.1; SJR指數(shù)：0.849; SNIP指數(shù)：0.706

發(fā)文數(shù)據(jù)：: Gold OA文章占比：2.21%; 研究類文章占比：44.93%; 年發(fā)文量：69; 自引率：0; 開源占比：0.0198; 出版撤稿占比：0; 出版國人文章占比：0.32; OA被引用占比：0.0238...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介Journal Of Drug Targeting期刊介紹

Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs.

Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.

期刊簡介Journal Of Drug Targeting期刊介紹

《Journal Of Drug Targeting》自1993出版以來，是一本醫(yī)學優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學研究結果，并為醫(yī)學各個領域的原創(chuàng)研究提供一個展示平臺，以促進醫(yī)學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或審查多年來某個重要領域的所有重要發(fā)展。該期刊特色在于及時報道醫(yī)學領域的最新進展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間：約2月
醫(yī)學
PHARMACOLOGY & PHARMACY
SCIE
中科院4區(qū)
非預警

Cite Score數(shù)據(jù)（2024年最新版）Journal Of Drug Targeting Cite Score數(shù)據(jù)

CiteScore：9.1
SJR：0.849
SNIP：0.706

學科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmaceutical Science	Q1	23 / 183	87%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎，針對的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區(qū)Journal Of Drug Targeting 中科院分區(qū)

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學科	分區(qū)	小類學科	分區(qū)
醫(yī)學	4區(qū)	PHARMACOLOGY & PHARMACY 藥學	4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎，運用科學計量學方法對國際、國內學術期刊依據(jù)影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機構的廣泛認可。

中科院分區(qū)表 將所有期刊按照一定指標劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個層次，類似于“優(yōu)、良、及格”等。最開始，這個分區(qū)只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區(qū)逐步發(fā)展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區(qū)趨勢圖

JCR分區(qū)Journal Of Drug Targeting JCR分區(qū)

2023-2024 年最新版

按JIF指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：PHARMACOLOGY & PHARMACY	SCIE	Q1	69 / 354	80.6%

按JCI指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：PHARMACOLOGY & PHARMACY	SCIE	Q2	94 / 354	73.59%

JCR分區(qū)的優(yōu)勢在于它可以幫助讀者對學術文獻質量進行評估。不同學科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質量可能是存在一定問題的。因此，JCR將期刊按照學科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計

國家/地區(qū)數(shù)量
CHINA MAINLAND140
USA50
India41
Iran27
Brazil14
South Korea13
Turkey12
Australia11
England10
Canada9

本刊中國學者近年發(fā)表論文

1、TGF beta 1/integrin beta 3 positive feedback loop contributes to acquired EGFR TKI resistance in EGFR-mutant lung cancer
Author: Wang, Tao; Zhang, Yali; Cheng, Hanyue; Li, Ling; Xu, Lu

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 3, pp. 269-277. DOI: 10.1080/1061186X.2022.2064480
2、Macrophage membrane biomimetic drug delivery system: for inflammation targeted therapy
Author: Zhang, Yulu; Long, Yu; Wan, Jinyan; Liu, Songyu; Shi, Ai; Li, Dan; Yu, Shuang; Li, Xiaoqiu; Wen, Jing; Deng, Jie; Ma, Yin; Li, Nan

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 3, pp. 229-242. DOI: 10.1080/1061186X.2022.2071426
3、Mucus- and pH-mediated controlled release of core-shell chitosan nanoparticles in the gastrointestinal tract for diabetes treatment
Author: Shi, Yanan; Liu, Lanze; Yin, Miaomiao; Zhao, Zhenyu; Liang, Yanzi; Sun, Kaoxiang; Li, Youxin

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 1, pp. 65-73. DOI: 10.1080/1061186X.2022.2104296
4、Advances, challenge and prospects in cell-mediated nanodrug delivery for cancer therapy: a review
Author: Wei, Wuhao; Zhang, Yuansheng; Lin, Zhizhe; Wu, Xin; Fan, Wei; Chen, Jianming

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 1, pp. 1-13. DOI: 10.1080/1061186X.2022.2104299
5、Poly-gamma-glutamic acid coating polymeric nanoparticles enhance renal drug distribution and cellular uptake for diabetic nephropathy therapy
Author: Wang, Qili; Han, Shunping; Zhu, Yongqin; Wang, Guowei; Chen, Danfei

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 1, pp. 89-99. DOI: 10.1080/1061186X.2022.2106488
6、Nano-composite hydrogels of Cu-Apa micelles for anti-vasculogenic mimicry
Author: Kang, Rui; Song, Mengdi; Fang, Zhou; Liu, Kehai

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 2, pp. 166-178. DOI: 10.1080/1061186X.2022.2115047
7、Progress in research and development of temozolomide brain-targeted preparations: a review
Author: Yang, Jiefen; Xu, Youfa; Fu, Zhiqin; Chen, Jianming; Fan, Wei; Wu, Xin

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 2, pp. 119-133. DOI: 10.1080/1061186X.2022.2119243
8、Transdermal delivery of celecoxib and alpha-linolenic acid from microemulsion-incorporated dissolving microneedles for enhanced osteoarthritis therapy
Author: Li, Jian; Tian, Xin; Wang, Kang; Jia, Yong; Ma, Fuguang

Journal: JOURNAL OF DRUG TARGETING. 2023; Vol. 31, Issue 2, pp. 206-216. DOI: 10.1080/1061186X.2022.2123492